Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7209
Peer-review started: January 14, 2022
First decision: March 8, 2022
Revised: April 18, 2022
Accepted: June 14, 2022
Article in press: June 14, 2022
Published online: July 26, 2022
Processing time: 177 Days and 9.6 Hours
Helicobacter pylori (H. pylori) infection is very common and affects a significant proportion of the world population. In contrast, the prevalence of small intestinal bacterial overgrowth (SIBO) in the general population is not well understood. There can be coexistence of both disease states in a given patient and their clinical symptoms may also overlap with one and another. There is no clear clinical guidelines for testing for and treating SIBO in patients with H. pylori infection. This review article explores the available evidence on the relationship between H. pylori infection and SIBO, diagnosis and treatment of these entities and also comments on associated non-gastrointestinal conditions.
Core Tip: This article explores the coexistence of small intestinal bacterial overgrowth (SIBO) in patients with Helicobacter pylori (H. pylori) infection including epidemiology and pathophysiologic mechanisms. It also reviews diagnosis and treatment of these entities and highlights current knowledge gaps and areas of future research. Currently, there are no guidelines for evaluation and management of co-existent SIBO in H. pylori infection.
